BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20871272)

  • 41. Temozolomide for malignant brain tumours.
    Batchelor T
    Lancet; 2000 Apr; 355(9210):1115-6. PubMed ID: 10791369
    [No Abstract]   [Full Text] [Related]  

  • 42. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.
    Pietanza MC; Kadota K; Huberman K; Sima CS; Fiore JJ; Sumner DK; Travis WD; Heguy A; Ginsberg MS; Holodny AI; Chan TA; Rizvi NA; Azzoli CG; Riely GJ; Kris MG; Krug LM
    Clin Cancer Res; 2012 Feb; 18(4):1138-45. PubMed ID: 22228633
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Recent advances in the medical treatment of glioma-temozolomide].
    Nishikawa R
    No To Shinkei; 2006 Dec; 58(12):1035-41. PubMed ID: 17193953
    [No Abstract]   [Full Text] [Related]  

  • 44. Effects of temozolomide in malignant brain tumours.
    Osoba D
    Lancet; 2000 Jul; 356(9226):342. PubMed ID: 11071219
    [No Abstract]   [Full Text] [Related]  

  • 45. Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
    Nagasawa DT; Chow F; Yew A; Kim W; Cremer N; Yang I
    Neurosurg Clin N Am; 2012 Apr; 23(2):307-22, ix. PubMed ID: 22440874
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term Results of a Survey of Prolonged Adjuvant Treatment with Temozolomide in Patients with Glioblastoma (SV3 Study).
    Rivoirard R; Falk AT; Chargari C; Guy JB; Mery B; Nuti C; Peoc'h M; Forest F; Garin C; Adjabi A; Hoarau D; Kawaye S; Almokhles H; Fournel P; Magné N
    Clin Oncol (R Coll Radiol); 2015 Aug; 27(8):486-7. PubMed ID: 25963856
    [No Abstract]   [Full Text] [Related]  

  • 47. [Temozolomide in patients with a glioblastoma multiforme: new developments].
    Bromberg JE; Postma TJ
    Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Temozolomide (Temodal) for treatment of primary brain tumours.
    MacConnachie AM
    Intensive Crit Care Nurs; 2000 Feb; 16(1):59-60. PubMed ID: 10790718
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases.
    Antonadou D; Paraskevaidis M; Sarris G; Coliarakis N; Economou I; Karageorgis P; Throuvalas N
    J Clin Oncol; 2002 Sep; 20(17):3644-50. PubMed ID: 12202665
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treatment of anaplastic astrocytomas and glioblastomas in children by the use of temozolomide (TMZ)].
    Zheludkova OG; Tarasova IS; Gorbatykh SV; Belogurova MB; Kumirova EV; Borodina ID; Prityko AG; Melikian AG; Shcherbenko OI
    Vopr Onkol; 2002; 48(3):356-60. PubMed ID: 12455362
    [No Abstract]   [Full Text] [Related]  

  • 51. Temozolomide for refractory anaplastic astrocytoma.
    Med Lett Drugs Ther; 1999 Dec; 41(1068):123-4. PubMed ID: 10987014
    [No Abstract]   [Full Text] [Related]  

  • 52. Simultaneous leptomeningeal and intramedullary spinal metastases in small cell lung carcinoma.
    Weissman DE; Grossman SA
    Med Pediatr Oncol; 1986; 14(1):54-6. PubMed ID: 3005816
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A small proportion of glioblastoma patients are probably eligible for concomitant/adjuvant temozolomide.
    O'Toole L; Khanduri S; Gerrard GE
    Clin Oncol (R Coll Radiol); 2007 May; 19(4):269. PubMed ID: 17433972
    [No Abstract]   [Full Text] [Related]  

  • 54. Seizure control: a secondary benefit of chemotherapeutic temozolomide in brain cancer patients.
    Hu A; Xu Z; Kim RY; Nguyen A; Lee JW; Kesari S
    Epilepsy Res; 2011 Aug; 95(3):270-2. PubMed ID: 21549564
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adding concomitant and adjuvant temozolomide to radiotherapy does not reduce health-related quality of life in people with glioblastoma.
    Hamilton DA
    Cancer Treat Rev; 2006 Oct; 32(6):483-6. PubMed ID: 16730911
    [No Abstract]   [Full Text] [Related]  

  • 56. Temozolomide: a novel oral alkylating agent.
    Danson SJ; Middleton MR
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):13-9. PubMed ID: 12113120
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical response following adjuvant Temozolomide in a patient with primary cerebral lymphoma.
    Strik HM; Spreer A; Nagel H; Jacob S; Jung W; Kitze B; Bähr M
    Anticancer Res; 2004; 24(6):4121-5. PubMed ID: 15736462
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Temozolomide for Treating Malignant Melanoma.
    Li RH; Hou XY; Yang CS; Liu WL; Tang JQ; Liu YQ; Jiang G
    J Coll Physicians Surg Pak; 2015 Sep; 25(9):680-8. PubMed ID: 26374366
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Temozolomide and cisplatin in the treatment of leptomeningeal metastatic involvement from melanoma: a case report.
    Salmaggi A; Silvani A; Eoli M; Lamperti E; Boiardi A
    Neurol Sci; 2002 Dec; 23(5):257-8. PubMed ID: 12528690
    [No Abstract]   [Full Text] [Related]  

  • 60. Adjuvant temozolomide: how long and how much?
    Franceschi E; Tosoni A; Brandes AA
    Expert Rev Anticancer Ther; 2008 May; 8(5):663-5. PubMed ID: 18471038
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.